MFSD4B

Across TCGA pan-cancer cohorts, MFSD4B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MFSD4B data layer compared with 26 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher MFSD4B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MFSD4B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ESCA, COAD, and UCEC are the cancer types where MFSD4B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	All	0.213	0.915	.005	9	view →
COAD	DFS	Median	III,IV	0.019	0.668	<.001	9	view →
UCEC	DFS	Median	All	1.000	0.630	.030	4	view →
KIRP	OS	Median	All	0.248	0.705	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MFSD4B–ESCA (OS)

Open the ESCA breakdown →